MDT · News · 20261006N
Hypertension Therapy Clinical Progress
Medtronic plc · 2026-10-06 · Importance 31 · Surprise 42 · In source text
Orchestra BioMed completed and exceeded enrollment in the pivotal BACKBEAT Global Pivotal Trial for its pacemaker-based hypertension therapy in collaboration with Medtronic. The trial randomized 330 patients and evaluates Atrioventricular Interval Modulation Therapy. Primary endpoint data are expected by spring 2027, after which Medtronic plans to seek FDA and global regulatory approvals if the results support the therapy.
Key facts
- The BACKBEAT Global Pivotal Trial aims to gather primary endpoint data by next spring to support potential regulatory filings. source
- The BACKBEAT Global Pivotal Trial for a pacemaker-based hypertension therapy conducted with Medtronic has randomized 330 patients. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The BACKBEAT Global Pivotal Trial aims to gather primary endpoint data by next spring to support potential regulatory filings. |